Thalidomide Maintenance Treatment in DLBCL

• Status: Recruiting
• Trial end date: 2023-12-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a randomized, multi-center,phase III study to evaluate the ability of thalidomide maintenance therapy to prolong relapse-free survival in diffuse large B cell lymphoma(DLBCL).

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Nanfang Hospital of Southern Medical University
• Treatments: Thalidomide

Criteria

Inclusion Criteria:

• NCCN-IPI>1,

• Known IPI, cell of origin and DHL at time of diagnosis,

• Negative pregnancy test,

• Men must agree not to father a child during the therapy,

• 6 to 8 cycles R-CHOP/like, total of 8 x Rituximab,

• CR, CRu

Exclusion Criteria:

• Transformed lymphoma,

• Secondary malignancy,

• HIV positive,

• Evidence of CNS involvement,

• Cardiac dysfunction (systolic ejection fraction <50%),

• Creatinine > 2.0 mg/dl